A Quebec research team has discovered two early plasma markers to detect Alzheimer's disease five years before its onset. The results of this recent study led by the doctoral student Mohamed Raâfet Ben Khedher and postdoctoral student Mohamed Haddad, directed by Professor Charles Ramassamy of the Institut national de la recherche scientifique (INRS), have been published in the prestigious scientific journal Alzheimer's & Dementia: Translational Research & Clinical Interventions (TRCI).
The diagnosis of Alzheimer's disease is usually based on a series of psychometric tests assessing cognitive function, brain imaging and cerebrospinal fluid analysis. Yet, these tests have their limitations.
The lumbar puncture is invasive, while brain imaging is expensive and not 100% reliable. This complicates regular follow-up."
Charles Ramassamy, Professor, INRS
Moreover, people with the disease are often being diagnosed at a late stage of the disease. "We need to find more and more early markers so we can act as soon as possible. When the disease is symptomatic, there is little, if any, way back," he explains.
The research team took up this challenge by discovering two markers, detectable through a blood test, enabling them to follow the progression of the disease. These markers are found in plasma extracellular vesicles, pockets that are released by all cells in the body and circulate in the bloodstream.
The variation of markers
The team focused specifically on the "sporadic" Alzheimer's disease, the most common type of the disease. It stems mainly from the presence of the APOE4 susceptibility gene, the E4 variant of the gene coding for apolipoprotein. Patients with this gene who developed the disease five years later had markers present that varied with the progression of the disease.
The research was carried out by analyzing blood samples collected as part of the Canadian Study of Health and Aging (CSHA). The population studied consisted of patients with cognitive problems, but not suffering from dementia, and only some of whom developed Alzheimer's disease. Professor Ramassamy hopes to analyze a larger population with pre- and post-disease samples.
This would allow him to determine the progression of markers after the onset of symptoms. His research on the markers located in the vesicles, opens up the possibility for studying other diseases, such as vascular dementia
Pitt researchers validate comprehensive blood test for Alzheimer's biomarkers